Chronic Stress Sends Gut Bacteria Into Tumors to Shield Them From Immune Attack

Cancer patients carry a heavy psychological burden, and a new study suggests that burden may be actively working against them at the molecular level. Researchers at Weill Cornell Medicine have traced a precise chain of events from chronic psychological stress, through the gut microbiome, all the way to the tumor microenvironment, where the end result is a suppressed immune system and faster-growing cancer. The findings were published June 25 in Cancer Cell by senior author Melody Zeng, an associate professor of immunology in pediatrics, and first author Hilal Bashir, a postdoctoral associate in the Zeng Lab.

How chronic stress drives gut bacteria into tumors

The mechanism begins in the adrenal glands. Chronic stress triggers a surge in glucocorticoids, the body's primary stress hormones. In the gut, elevated glucocorticoids activate receptors on the cells lining the intestinal wall, weakening the gut barrier. That structural failure matters enormously: it allows specific gut bacteria to escape into the bloodstream and travel to distant tumor sites. Research on gut microbiota pathways linking chronic stress to tumor progression has documented how stress-induced dysbiosis reduces microbial diversity and enriches potentially harmful species, but the Weill Cornell work takes that picture several steps further by identifying what those escaped bacteria actually do once they reach a tumor.

In mouse models of colorectal cancer and melanoma, the bacterium that dominated gut-to-tumor migration was Enterococcus gallinarum. The bacteria themselves were not the final actor. Inside the tumor, the bacterial cells harbored small viruses called bacteriophages, or phages, which burst out of the bacteria and released their DNA into the surrounding tissue. That phage DNA activated a receptor called TLR9 on cancer-associated fibroblasts, the structural support cells woven through most solid tumors. TLR9 activation caused those fibroblasts to produce their own supply of glucocorticoids locally, compounding the systemic stress signal already present. The result was a steep suppression of antigen-specific germinal center B cell responses, one of the key branches of antitumor immunity.

Cancer patients face a compounded immune disadvantage

The real-world stakes are significant. Cancer patients typically live with chronic psychological stress from diagnosis onward, and this study suggests that stress is not merely an emotional burden but a physiological one that actively remodels the tumor's immune environment. As Zeng noted, "our findings open up many new research directions, with possibilities for new treatments and prognostic tests for cancer patients."

The implications extend to treatment protocols as well. Glucocorticoids are commonly prescribed to cancer patients to manage inflammation and chemotherapy side effects. Bashir flagged the tension directly: "These findings also underscore the importance of stress management in cancer, and raise questions about existing therapeutic approaches that sometimes involve giving patients glucocorticoids." In other words, a standard supportive therapy may be feeding the same suppressive loop the study describes. Work on modulating the gut microbiome to improve cancer therapy has shown that microbiome interventions can enhance the efficacy of immune checkpoint inhibitors, and this new axis gives researchers a more defined molecular target to work with.

Mouse models and human tumor samples converge on the same mechanism

The study's credibility rests partly on its dual-track evidence. In mice, the team confirmed the mechanism by comparing tumor growth in germ-free animals and antibiotic-treated animals against controls, demonstrating that the presence of gut bacteria was necessary for the immune suppression to occur. They also showed they could block the effect either by targeting TLR9 signaling on cancer-associated fibroblasts or by injecting antibiotics directly into tumors.

Critically, the findings were not confined to rodents. In human colorectal tumor samples, the researchers isolated phage-laden Klebsiella pneumoniae, a different species from the mouse-dominant Enterococcus gallinarum but operating through the same phage-release mechanism. Human brain tumor samples pointed to Enterococcus faecium and associated phages. Prior gut virome research in colorectal cancer mouse models had already suggested that virome dysbiosis impairs antitumor immunity; the Zeng lab's work identifies the molecular receptor that translates that viral signal into immune suppression. Earlier work had also shown that certain gut bacteria can suppress adaptive antitumor immune responses, but linking that suppression to phage DNA released inside the tumor itself is a new mechanistic step.

Open questions about tumor phages, glucocorticoid therapy, and broader species

Several important limitations remain. The study was conducted primarily in preclinical mouse models, and while the human tumor data are suggestive, causal evidence in human patients has not yet been established. The investigators identified E. gallinarum in mice and K. pneumoniae and E. faecium in human samples, indicating that multiple bacterial species likely participate in this process, particularly those capable of surviving outside the gut. Which species matter most in which cancer types is unresolved. Understanding how gut microbiota drive immune escape across non-gastrointestinal malignancies remains an open problem; the precise mechanisms may differ substantially between colorectal cancer, melanoma, and brain tumors.

There is also the unresolved question of glucocorticoid-based supportive therapies. If exogenous glucocorticoids weaken the gut barrier and feed the same cascade described in the study, oncologists may need to weigh that risk against the anti-inflammatory benefits, a clinical trade-off that will require dedicated trials to evaluate.

What comes next: TLR9 blockade, phage detection, and stress-targeted trials

The Zeng lab is now studying which therapeutic approach will work best against this process. The two candidates demonstrated in the current study, blocking TLR9 on cancer-associated fibroblasts and injecting antibiotics into tumors, are both proof-of-concept interventions that will need safety and efficacy testing before any clinical application. The team also raised the possibility that detecting phages in tumor tissue could have prognostic value, offering an early signal of immune suppression in a given patient.

Longer term, phage therapy designed to selectively modulate gut bacteria in colorectal cancer is an emerging strategy that could, in principle, be used either to remove phage-carrying species before they infiltrate tumors or to repurpose phage biology toward therapeutic ends. The new stress-phage-fibroblast-B cell axis the Weill Cornell team has described gives that entire research space a clearer mechanistic foundation to build on.

Evidence rating

INVESTIGATIONAL — 84/100

Caveats:

• The core mechanistic findings come from mouse models; human tumor samples provide supporting correlational evidence only, not proof that the same causal chain operates in humans.
• The primary bacterial species implicated (Enterococcus gallinarum) was identified in mouse models; human tumor data pointed to different species (Klebsiella pneumoniae, Enterococcus faecium), so the mechanism may vary across cancer types and individuals.
• This is a single study and has not yet been independently replicated.
• The source article is a press release, not the peer-reviewed paper itself; specific effect sizes and statistical details were not available for review.

Preclinical study combining mouse cancer models with correlational analysis of human tumor samples. Demonstrates a detailed mechanistic chain linking chronic stress, gut bacterial translocation, and tumor-resident phage activity to local immune suppression, but causal evidence in humans has not been established. A single study not yet independently replicated; human data are associative.

References

1. Stress-linked gut viruses may help tumors evade immune system | Cornell Chronicle. https://news.cornell.edu/stories/2026/06/stress-linked-gut-viruses-may-help-tumors-evade-immune-system
2. Qing Li, Siyuan Xia, Xian Zhang, Yuqiang Liu, Xue Xiao, Jinlin Yang (2026). Gut Microbiota-Driven Pathways Linking Chronic Stress to Tumor Progression. International Journal of Biological Sciences. https://doi.org/10.7150/ijbs.119630
3. Young Seok Cho, Kai Han, Jin Xu, James J. Moon (2024). Novel strategies for modulating the gut microbiome for cancer therapy. Advanced Drug Delivery Reviews. https://doi.org/10.1016/j.addr.2024.115332
4. Hui Huang, Ying Yang, Xiaojiao Wang, et al. (2024). Gut virome dysbiosis impairs antitumor immunity and reduces 5-fluorouracil treatment efficacy for colorectal cancer. Frontiers in Oncology. https://doi.org/10.3389/fonc.2024.1501981
5. Gut Microbiota and Tumor Immune Escape: A New Perspective for Improving Tumor Immunotherapy. NIH. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10302303/
6. Mutebi John Kenneth, Jung-Sheng Chen, Chuan-Yin Fang, et al. (2025). Exploring the therapeutic potential of bacteriophage-mediated modulation of gut microbiota towards colorectal cancer. International Journal of Antimicrobial Agents. https://doi.org/10.1016/j.ijantimicag.2025.107585